Allgenesis Biotherapeutics
Taipei, Taiwan· Est.
Taiwan biotech developing bispecific ocular biologics for DME, dry eye and AMD.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan biotech developing bispecific ocular biologics for DME, dry eye and AMD.
OphthalmologyRetinal DiseasesOcular Surface Diseases
Technology Platform
Bispecific Fc‑fusion proteins combining anti‑VEGF with disintegrin motifs, plus FPR agonists and tyrosine‑kinase inhibitors for ocular indications.
Opportunities
Advancing bispecific ocular biologics could capture market share in DME and AMD, while the dry eye program taps a high‑growth, underserved segment.
Risk Factors
Clinical development setbacks, limited financial runway, and intense competition from established ophthalmic biologics manufacturers.
Competitive Landscape
Competes with large pharma (e.g., Regeneron, Roche, Novartis) and niche biotech firms developing anti‑VEGF and multi‑target ocular therapies; differentiation relies on bispecific design and novel mechanisms.